Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 2Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 471Neoplasms 328Colorectal Neoplasms 235Carcinoma, Non-Small-Cell Lung 234Lung Neoplasms 200Prostatic Neoplasms 179Carcinoma, Hepatocellular 174Stomach Neoplasms 138Pancreatic Neoplasms 126Leukemia, Myeloid, Acute 114Uterine Cervical Neoplasms 110Rectal Neoplasms 105Multiple Myeloma 94Recurrence 89Squamous Cell Carcinoma of Head and Neck 84Head and Neck Neoplasms 79Neoplasm Metastasis 76Ovarian Neoplasms 75Brain Neoplasms 71Colonic Neoplasms 68Glioblastoma 67Esophageal Neoplasms 66Triple Negative Breast Neoplasms 65Endometrial Neoplasms 58Precursor Cell Lymphoblastic Leukemia-Lymphoma 56Small Cell Lung Carcinoma 54Disease 54Motor Activity 53Hematologic Neoplasms 53Glioma 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × OTHER × HER2 Positive Breast Cancer × Clear all
NCT06868017 2025-03-10

Randomized Controlled Clinical Study of Efficacy and Safety of Initumab Combined with Pyrrotinib and Chemotherapeutic Agents in Neoadjuvant Therapy for HER2-positive Breast Cancer with Different Treatment Cycles

The First Hospital of Jilin University

Phase 4 Not yet recruiting
208 enrolled
Breast

HER2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡